On October 22, 2026, RoboSense (02498.HK) edged lower. As of 15:01, it was quoted at HK$13.68, down 8.00%.
SMIC (00981.HK) fell 6.29% to HKD 46.820; its 8-inch utilisation hit 95.8% in Q3, and Samsung's Giheung fab shutdown will cut 50,000 wafers of monthly capacity.
UBTECH ROBOTICS (09880.HK) fell 4.31% to HKD 64.450; it signed a Ras Al Khaimah government MoU, and Tesla said Optimus could be sold externally by end-2027.
TransThera-B (02617.HK) said Yochanra® began nationwide supply after shipping on Sept 17, 2026, with the first prescription issued in Beijing the same day.
SSY Group (02005.HK) said labetalol hydrochloride won NMPA bulk drug registration for hypertension; its injection serves gestational hypertension emergencies.
On 21 Oct 2026, XUANZHUBIO-B (02575.HK) said Phase III data showed anlarazole sodium met its endpoint in reflux oesophagitis, with 88.4% healing in FAS.
On 21 Oct 2026, KINTOR PHARMA-B (09939.HK) said its KT-939 inhibitor won a Chinese invention patent grant notice; an NMPA cosmetic filing was filed on 18 Sept.
On October 21, the HSTECH fell 1.26% below 4,000 and the HSI lost 0.90%. MONTAGETECH led AI concept stocks with an 8.97% gain, while TENCENT fell 4.04%.
On 21 October 2026, LONGBIO-B (01779.HK) reported Phase II data for LP-005 in PNH, with 100% haemolysis control at 1,200 mg and 1,500 mg and no related SAEs.
On October 21, 2026, XPENG-W (09868.HK) traded weaker. As of 14:27, it was quoted at HK$37.28, down 0.85%.
HUA HONG GRACE (01347.HK) fell 0.20% to HKD 73.200; mature-node foundry prices may rise 4% to 8% in Q1 2027, and its 8-inch utilisation hit 109.5% in Q3.
EXCELLAND ROBOT (03231.HK) fell 1.10% to HKD 34.320; commercial cleaning robots cut labour costs 28%, and its RaaS revenue reached 17.2% of the total in H1.
On 21 October 2026, ABBISKO-B (02256.HK) said its FGFR2/3 inhibitor lavengratinib (ABSK061) won EMA orphan designation for achondroplasia.
On 21 October 2026, SBP GROUP (01177.HK) said its TQC2731 TSLP antibody completed enrolment in a Phase III trial for chronic rhinosinusitis with nasal polyps.
On 21 October 2026, HUTCHMED (00013.HK) closed its HMPL-A830 licence deal with GSK, covering territories outside Greater China, for a USD 110 million upfront.
On 21 October 2026, ASCENTAGE (06855.HK) said its lisaftoclax won breakthrough therapy status from China's CDE for first-line CLL/SLL with acalabrutinib.
